docetaxel
Selected indexed studies
- Docetaxel. (J Clin Oncol, 1995) [PMID:7595719]
- Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. (Theranostics, 2022) [PMID:35836810]
- Docetaxel as a Model Compound to Promote HDL (High-Density Lipoprotein) Biogenesis and Reduce Atherosclerosis. (Arterioscler Thromb Vasc Biol, 2023) [PMID:36861478]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Docetaxel. (1995) pubmed
- Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. (2022) pubmed
- Docetaxel as a Model Compound to Promote HDL (High-Density Lipoprotein) Biogenesis and Reduce Atherosclerosis. (2023) pubmed
- Docetaxel-induced Flagellate Erythema - Case Report and Brief Review. (2023) pubmed
- The interactions of docetaxel with tumor microenvironment. (2023) pubmed
- Docetaxel Rechallenge in Patients with Metastatic Prostate Cancer: A Comprehensive Review. (2020) pubmed
- Docetaxel for the treatment of bladder cancer. (2015) pubmed
- Docetaxel-induced Acute Myositis. (2023) pubmed
- [Docetaxel and ovarian cancer]. (2004) pubmed
- DOCETAXEL-INDUCED PIGMENTARY MACULOPATHY. (2025) pubmed